InsightPFA Trial of the LotosPFA Catheter

NCT06014996 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2025-08-17

No results posted yet for this study

Summary

This trial aims to determine whether the InsightPFA for PVI is as effective and safe as standard RFA in the treatment of symptomatic paroxysmal AF.

Conditions

  • Arrhythmias, Cardiac
  • Paroxysmal Atrial Fibrillation

Interventions

DEVICE

Pulsed Field Ablation (PFA) Therapy

In the test group, subjects will undertake PVI using the PFA system including a nanosecond-scale pulsed field generator (InRythm, Insight Lifetech, Shenzhen, China), a lotos catheter that is expandable over the wire (LotosPFA, Insight Lifetech), and a customized 12-French steerable sheath (InBridge, Insight Lifetech).

DEVICE

Radiofrequency Ablation(RAF)Therapy

In the control group, subjects will undergo PVI using an RFA system including CARTO VISITAG Module and the THERMOCOOL SMARTTOUCH Catheter (Biosense Webster Inc., Diamond Bar, CA, USA). PVI was performed with AI values of 400-450 in the anterior, 300-350 at the posterior wall of the LA.

Sponsors & Collaborators

  • Insight Lifetech Co., Ltd.

    collaborator INDUSTRY
  • Guangdong Provincial People's Hospital

    collaborator OTHER
  • Beijing Anzhen Hospital

    collaborator OTHER
  • Sir Run Run Shaw Hospital

    collaborator OTHER
  • Shanghai Zhongshan Hospital

    collaborator OTHER
  • The Affiliated People's Hospital of Ningbo University

    collaborator OTHER_GOV
  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER
  • Nanfang Hospital, Southern Medical University

    collaborator OTHER
  • Xiamen Cardiovascular Hospital, Xiamen University

    collaborator OTHER
  • Yan'an Affiliated Hospital of Kunming Medical University

    collaborator OTHER
  • Weifang People's Hospital

    collaborator OTHER
  • Insight Medtech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-04
Primary Completion
2025-06-09
Completion
2025-07-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014996 on ClinicalTrials.gov